http://medicalxpress.com/ en-us Medical Xpress internet news portal provides the latest news on Health and Medicine. Patients with pulmonary arterial hypertension (PAH) receiving combination therapy with intravenous (IV) PGI2 may suffer from greater disease burden compared with those receiving monotherapy or combination therapy, excluding IV PGI2. http://medicalxpress.com/news/2012-10-pulmonary-hypertension-combination-therapy-greater.html Diseases, Conditions, Syndromes Mon, 22 Oct 2012 03:26:50 EST news270095200 Swiss pharmaceutical giant Novartis said Sunday the expiry of a US patent for its leading hypertension drug Diovan caused a drop in turnover that could last into the first half of 2013. http://medicalxpress.com/news/2012-10-novartis-chief-sales-dip-mid-.html Medications Sun, 07 Oct 2012 05:58:03 EST news268808275 In a special report in The Lancet, researchers from Queen Mary, University of London (UK) argue that pending cases against India's patent laws threaten public health and misinterpret international intellectual property agreements. http://medicalxpress.com/news/2012-09-india-patent-laws-pressure-lancet.html Medications Mon, 10 Sep 2012 10:55:50 EST news266493342 Novartis AG and Incyte Corp. said Tuesday that European Union regulators approved their blood cancer drug Jakavi. http://medicalxpress.com/news/2012-09-eu-novartis-incyte-blood-cancer-drug.html Medications Tue, 04 Sep 2012 08:10:37 EST news265965018 (HealthDay)—The U.S. Food and Drug Administration has approved Afinitor Disperz (everolimus tablets for oral suspension), the first form of the anti-cancer drug Afinitor to be created especially for children. http://medicalxpress.com/news/2012-08-afinitor-disperz-rare-pediatric-cancer.html Medications Wed, 29 Aug 2012 19:10:01 EST news265483950 A researcher at Moffitt Cancer Center and his international team of colleagues have reported study results on a novel multireceptor-targeted somatostatin analogue called pasireotide (SOM230) manufactured by Novartis Pharma AG. The Phase II, open-label, multicenter study in patients with advanced neuroendocrine tumors (NET) whose symptoms were no longer responsive to octreotide LAR therapy found that the drug was effective and well tolerated in controlling patient symptoms. http://medicalxpress.com/news/2012-08-drug-patients-neuroendocrine-tumors.html Cancer Mon, 06 Aug 2012 13:09:02 EST news263477333 (AP) — Swiss pharmaceutical company Novartis AG reported a net profit of $2.73 billion during the second quarter, as new drugs and acquisitions offset patent expirations, lower sales of generic medicines and the strengthening dollar. http://medicalxpress.com/news/2012-07-drugs-shore-novartis-q2.html Other Thu, 19 Jul 2012 03:40:04 EST news261887089 A new set of computer models has successfully predicted negative side effects in hundreds of current drugs, based on the similarity between their chemical structures and those molecules known to cause side effects, according to a paper appearing online this week in the journal Nature. http://medicalxpress.com/news/2012-06-successfully-drug-side-effects.html Medical research Mon, 11 Jun 2012 13:27:50 EST news258640062 Greece's highly uncertain future has forced businesses into a quasi hand-to-mouth existence, with one of the most alarming effects a shortage of medicines, including for the seriously ill. http://medicalxpress.com/news/2012-06-greek-crisis-medicine-shortages.html Medications Wed, 06 Jun 2012 07:42:47 EST news258187362 European Union regulators have given Swiss pharmaceutical group Novartis a green light to market its drug Signifor as a treatment for Cushing's disease, the company said Wednesday. http://medicalxpress.com/news/2012-04-eu-novartis-drug-signifor-cushing.html Medications Wed, 25 Apr 2012 09:40:01 EST news254564624 (AP) -- Drug maker Novartis says it is taking legal action in Britain to make hospitals use an eye drug that costs 700 pounds ($1,130) per shot instead of a cheaper one that costs 60 pounds ($97). http://medicalxpress.com/news/2012-04-novartis-uk-hospitals-drug.html Medications Tue, 24 Apr 2012 07:35:08 EST news254471681 (Medical Xpress) -- A research team from drug maker Novartis has discovered a compound that spurs cartilage growth in mice. As they describe in their paper published in the journal Science, the team has found that when a compound with molecules of kartogenin in it comes in contact with certain kinds of stem cells, chondrocytes develop, resulting in new cartilage growth, possibly paving the way perhaps, to a long sought treatment for osteoarthritis. http://medicalxpress.com/news/2012-04-team-compound-spur-cartilage-growth.html Medical research Fri, 06 Apr 2012 09:50:50 EST news252924623 Swiss pharmaceutical group Novartis said Monday the European Union will allow it to expand its use of the drug Glivec to treat certain rare forms of gastrointestinal cancer. http://medicalxpress.com/news/2012-02-novartis-eu-glivec.html Medications Mon, 27 Feb 2012 08:29:24 EST news249553758 One hundred million treatments of Coartem Dispersible (artemether-lumefantrine), an antimalarial developed especially for children with Plasmodium falciparum malaria, have been delivered by Novartis to 39 malaria-endemic countries, Medicines for Malaria Venture (MMV) announced today. http://medicalxpress.com/news/2012-02-delivery-child-friendly-antimalarial-million.html Diseases, Conditions, Syndromes Wed, 22 Feb 2012 09:39:31 EST news249125965 (Medical Xpress) -- A University of Alberta researcher and Canada Excellence Research Chair in Virology has made the discovery of a vaccine that will potentially help combat hepatitis C. Michael Houghton, who led the team that discovered the hepatitis C virus in 1989, announced his findings at the Canada Excellence Research Chairs Summit in Vancouver this afternoon. Currently, there are no vaccines against the disease available. http://medicalxpress.com/news/2012-02-vaccine-hep.html Diseases, Conditions, Syndromes Thu, 16 Feb 2012 07:34:41 EST news248600065 Key players in the pharmaceutical industry pledged on Monday to donate 14 billion drug treatments as part of a new, global push to eradicate tropical diseases. http://medicalxpress.com/news/2012-01-drug-firms-tropical-disease.html Diseases, Conditions, Syndromes Mon, 30 Jan 2012 08:57:01 EST news247136198 A multiple sclerosis drug made by industry giant Novartis is under investigation after at least 11 patients taking the medicine died. http://medicalxpress.com/news/2012-01-novartis-drug-deaths.html Medications Fri, 20 Jan 2012 13:29:55 EST news246288586 Researchers at St. Michael's Hospital have published the first detailed figures showing the risk of using the prescription drug Rasilez in combination with certain other blood pressure-lowering medications. http://medicalxpress.com/news/2012-01-rasilez-blood-pressure-lowering-drugs.html Medications Thu, 12 Jan 2012 11:10:01 EST news245586481 (AP) -- The Food and Drug Administration is warning patients about a potential mix-up between powerful prescription pain drugs and common over-the-counter medications like Excedrin and Gas-X made at a Novartis manufacturing plant. http://medicalxpress.com/news/2012-01-fda-pill-mix-up-endo-painkillers.html Medications Mon, 09 Jan 2012 11:16:19 EST news245330170 Swiss pharmaceutical firm Novartis said Sunday it was recalling four different products sold over the counter in the United States over reports of a malfunction at one of its plants. http://medicalxpress.com/news/2012-01-swiss-pharma-giant-novartis-recalls.html Medications Sun, 08 Jan 2012 16:44:52 EST news245263480 (AP) -- Doctors were mostly hoping to prevent complications and relapses when they gave young women a medicine to keep their bones strong during breast cancer treatment. Seven years later, they found it did more than that: The bone drug improved survival, as much as many chemotherapies do. http://medicalxpress.com/news/2011-12-bone-drug-boosts-breast-cancer.html Cancer Fri, 09 Dec 2011 03:10:01 EST news242621950 (AP) -- Breast cancer experts are cheering what could be some of the biggest advances in more than a decade: two new medicines that significantly delay the time until women with very advanced cases get worse. http://medicalxpress.com/news/2011-12-big-breast-cancer-drugs.html Cancer Thu, 08 Dec 2011 05:30:02 EST news242540493 The first drug to treat a rare disorder that causes red blood cells to build up inside bone marrow was cleared Wednesday by the Food and Drug Administration http://medicalxpress.com/news/2011-11-fda-drug-bone-marrow-disorder.html Medications Wed, 16 Nov 2011 12:59:10 EST news240670722 Swiss pharmaceutical giant Novartis announced 2,000 job losses Tuesday, mostly in Switzerland and the United States, while reporting net profits of $3.53 billion (2.5 billion euros) for the third quarter. http://medicalxpress.com/news/2011-10-novartis-job-losses-profits.html Other Tue, 25 Oct 2011 04:47:01 EST news238736805 (AP) -- In a case that could affect India's role as drug provider to the developing world, the Supreme Court began hearing arguments Tuesday over whether the government had the right to deny a patent to Swiss drugmaker Novartis AG for its lifesaving cancer treatment Gleevec. http://medicalxpress.com/news/2011-09-novartis-patent-indian-court.html Medications Tue, 06 Sep 2011 10:22:55 EST news234523359 (Medical Xpress) -- Scientists from the U.S. Food and Drug Administration and the pharmaceutical company Novartis announced today in the journal Science Translational Medicine that they have developed a new adjuvant, or compound that increases the immune response, to add to the current flu vaccines. This adjuvant will allow flu vaccine producers to cut the antigen needed in half and allow for more flu vaccines to be made. This adjuvant would aid in the effectiveness of the flu vaccine while also creating a way to double the U.S. flu vaccine supply. http://medicalxpress.com/news/2011-06-flu-vaccine.html Medications Thu, 02 Jun 2011 07:19:00 EST news226217912 Researchers from Boston University School of Medicine (BUSM) have discovered new details about the underlying mechanisms of skin hardening syndromes. The team connected pharmacological properties of the Novartis Pharma AG drug called balicatib to the skin disorder for the first time after investigating adverse reactions suffered by patients participating in a clinical trial for the treatment of osteoporosis. These findings appear online in the Journal of the American Academy of Dermatology. http://medicalxpress.com/news/2011-05-underlying-mechanisms-skin-hardening-syndromes.html Diseases, Conditions, Syndromes Tue, 17 May 2011 14:35:40 EST news224861700